Vertex Pharmaceuticals Incorporated
VRTXLast close · Oct 16, 2026499.74−9.01 (−1.77%)
Market cap$126.7B
13 firms' latest targets, last 90 days: median $608.00 ($442.00–$665.00), 22% above the last close.
Price and published targets
Each firm's latest target
| Date | Firm | Target | Change | Vs price now |
|---|---|---|---|---|
| 2026-10-08 | RBC Capital | $576.00 | ▲ 1% | +15% |
| 2026-09-28 | UBS | $615.00 | ▲ 5% | +23% |
| 2026-09-23 | Jefferies | $640.00 | ▲ 10% | +28% |
| 2026-09-22 | H.C. Wainwright | $641.00 | ▲ 8% | +28% |
| 2026-09-01 | Morgan Stanley | $665.00 | ▲ 8% | +33% |
| 2026-09-01 | Goldman Sachs | $653.00 | — | +31% |
| 2026-08-11 | Bernstein | $608.00 | ▲ 6% | +22% |
| 2026-08-10 | Wolfe Research | $562.00 | — | +12% |
| 2026-08-05 | Truist | $565.00 | ▲ 1% | +13% |
| 2026-08-05 | Barclays | $617.00 | = 0% | +23% |
| 2026-08-04 | Cantor Fitzgerald | $595.00 | ▲ 1% | +19% |
| 2026-08-04 | Canaccord Genuity | $442.00 | ▲ 1% | -12% |
| 2026-08-04 | Stifel | $500.00 | ▲ 7% | +0% |
Consensus estimates
| FY | Revenue | YoY | EPS | YoY | Revenue range | EPS range | Analysts |
|---|---|---|---|---|---|---|---|
| 2023reported | $9.9B | +11% | $13.89 | +8% | est. $9.9B+0% | est. $15.03 | 20 |
| 2024reported | $11.0B | +12% | -$2.08 | -115% | est. $10.9B+1% | est. $0.46 | 21 |
| 2025reported | $12.0B | +9% | $15.32 | — | est. $12.0B+0% | est. $18.48 | 20 |
| 2026 | $13.2B | +10% | $18.68 | +1% | $13.2B–$13.4B | $17.51–$19.20 | 15 |
| 2027 | $14.7B | +11% | $21.05 | +13% | $13.9B–$16.2B | $18.56–$23.54 | 14 |
| 2028 | $16.5B | +12% | $25.16 | +19% | $15.1B–$17.6B | $21.83–$28.40 | 13 |
| 2029 | $18.6B | +13% | $29.88 | +19% | $17.8B–$19.4B | $28.39–$31.56 | 11 |
| 2030 | $20.5B | +11% | $34.08 | +14% | $19.7B–$21.4B | $32.39–$36.01 | 6 |
Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.